Longenesis announces a late seed round for the amount of $1.2 million led by Rustam Gilfanov. Ilya Suharenko, a private investor and one of the LongeVC’s Managing Partners also participated in the round bringing his 17 years of experience in traditional banking.
Longenesis is developing tools to expedite biomedical research digitization. Its primary goal is to increase patient engagement and trust in research organizations and study sponsors, as well as enable clinical sites and patient advocacy groups to compliantly expose their patients and data for biomedical research.
Medical data is sensitive and confidential, which presents challenges for researchers who require large and detailed datasets. By introducing digitalization and consent-enabled showcasing of biomedical assets, as well as emphasizing patient-centricity, Longenesis will contribute to cost reduction and acceleration of biomedical research.
The proceeds will be used to expand the Longenesis presence in key markets and scale the deployment of its core products. Longenesis services revolve around three distinct products:
Curator enables research institutions such as hospitals or biobanks to publish anonymized patient datasets and benefit from collaboration from interested third parties.
Patient confidentiality is ensured because the data does not contain any personally identifiable information. However, the enhanced presentation and accessibility of the data enable third parties to quickly determine whether it is relevant to their research projects accelerating what was previously a difficult, slow, costly, and tedious process. This expands the research potential of personal data while preserving privacy and adhering to regional regulatory requirements.
Additionally, researchers from universities, government agencies, and artificial intelligence companies can use the data for advanced analyses.
Themis is an API-based consent management tool for patients enrolled in medical studies and clinical trials. This ensures complete patient-centricity and empowers patients to participate actively in research studies and gain a better understanding of their contribution.
“Flexible digital consent enables study participants to exert control over their participation in the study by reading the informed consent document calmly and signing or revoking it at any time. This opportunity strengthens public trust in researchers and science in general,” Lilian Tzivian, Ph.D., a renowned epidemiologist at the University of Latvia, says.
Engage simplifies the process of onboarding new patients with a single click on the research organization link.
Additionally, Engage enables the management of patient contact information for follow-up questions and consent for their participation in research projects. Moreover, it includes exporting and monitoring tools that enable analysis throughout the medical study.
Longenesis has already deployed its solutions with a number of governments, biopharmaceutical companies, and academic consortia in the EU, the Middle East, and Asia providing data curation and patient interaction services.
In addition, the company has recently announced a collaboration with Medtronic. The Medtronic-Longenesis cooperation that also includes diabetic patient organizations will serve as a testbed for digitalizing patient engagement in research and advocacy efforts.
“Advocacy is a critical component of the patient organization’s work, but it has also been a significant struggle in the past. To ensure that patients’ needs and wishes are taken seriously and that their best interests are prioritized, we must maintain an open dialogue with them. Numerous factors obstruct this process, including their varying abilities and the inherent distrust associated with any chronic condition. As a result, we are thrilled to cooperate with Longenesis. We believe that their patient engagement and data curation solutions will provide us with the necessary access to diabetic patients and potential research partners. We hope that the current project is only the beginning,” Indra Stelmane, Ph.D., endocrinologist and the President of the Latvian Diabetes Federation, says.
Supporters of Longenesis
LongeVC is a driving force behind Longenesis. LongeVC is the investment fund that focuses on industrial development, fundraising, and start-up development for biotech companies.
LongeVC’s primary objective is to invest in companies that are pioneering new technologies in the longevity industry. LongeVC’s Managing Partner, Garri Zmudze, noted:
“Compliance with regulatory requirements regarding access to clinical data and patient cohorts will continue to be a critical success factor for any biotech or longevity-focused venture. We believe that Longenesis possesses all of the necessary characteristics to serve as the backbone of compliant biomedical data utilization in the coming years.”
Rustam Gilfanov, a business angel and Venture Partner of LongeVC, who led the investment round, commented on the role of digitization in biotechnology and medical research:
“Biotechnology is advancing rapidly today, intending to digitize processes that were previously entirely dependent on humans and excessively manual. Recent breakthroughs in AI-driven drug discovery are an excellent illustration of this, with many more to come. Digitalization, transparency, and compliance in biomedical data asset access are critical for the replication and scaling of such innovations. The fund seeks to develop such businesses. This is the way we will live in the future.”
Must have tools for startups - Recommended by StartupTalky
Subscribe to StartupTalky
Get the latest insights delivered to you right in your inbox